The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice

[1]  D. Roukos,et al.  Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use? , 2007, Annals of Surgical Oncology.

[2]  G. Harewood.  Treatment of rectal cancer. , 2006, The New England journal of medicine.

[3]  L. Schwartz,et al.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[5]  D. Cunningham,et al.  Treatment of gastric cancer - Reply , 2006 .

[6]  A. Malani,et al.  Treatment of gastric cancer. , 2006, The New England journal of medicine.

[7]  G. Harewood.  Treatment of gastric cancer. , 2006, The New England journal of medicine.

[8]  K. Jani.  Treatment of gastric cancer. , 2006, The New England journal of medicine.

[9]  D. Peake,et al.  Treatment of gastric cancer. , 2006, The New England journal of medicine.

[10]  H. Boot,et al.  Treatment of gastric cancer. , 2006, The New England journal of medicine.

[11]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[12]  A. Norman,et al.  Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Berlin,et al.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.

[14]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Putter,et al.  Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  T. Hickish,et al.  Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[18]  J. Ajani,et al.  Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of intergroup study INT-0116 (SWOG 9008) , 2001 .

[19]  S. Hundahl,et al.  The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy , 2000, Cancer.

[20]  T. Hickish,et al.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial , 1999, British Journal of Cancer.

[21]  P. Fayers,et al.  Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial , 1999, British Journal of Cancer.

[22]  I. Judson,et al.  First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial , 1997 .

[23]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.